247 related articles for article (PubMed ID: 33690159)
1. KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.
Poluri RTK; Paquette V; Allain ÉP; Lafront C; Joly-Beauparlant C; Weidmann C; Droit A; Guillemette C; Pelletier M; Audet-Walsh É
Endocr Relat Cancer; 2021 Apr; 28(4):257-271. PubMed ID: 33690159
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of MicroRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5.
Guan C; Zhang L; Wang S; Long L; Zhou H; Qian S; Ma M; Bai F; Meng QH; Lyu J
Cancer Biol Ther; 2019; 20(8):1149-1161. PubMed ID: 31002531
[TBL] [Abstract][Full Text] [Related]
3. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
Frigo DE; Sherk AB; Wittmann BM; Norris JD; Wang Q; Joseph JD; Toner AP; Brown M; McDonnell DP
Mol Endocrinol; 2009 Sep; 23(9):1385-96. PubMed ID: 19460858
[TBL] [Abstract][Full Text] [Related]
4. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
[TBL] [Abstract][Full Text] [Related]
5. circCRKL suppresses the progression of prostate cancer cells by regulating the miR-141/KLF5 axis.
Nan C; Wang Y; Yang S; Chen Y
Pathol Res Pract; 2020 Nov; 216(11):153182. PubMed ID: 32919302
[TBL] [Abstract][Full Text] [Related]
6. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
[TBL] [Abstract][Full Text] [Related]
7. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
8. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
9. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
10. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
[TBL] [Abstract][Full Text] [Related]
12. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
Kim Y; Kim J; Jang SW; Ko J
Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
[TBL] [Abstract][Full Text] [Related]
13. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
14. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
15. Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.
Jain P; Clermont PL; Desmeules F; Zoubeidi A; Neveu B; Pouliot F
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626088
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
Cheng Y; Wang D; Jiang J; Huang W; Li D; Luo J; Gu W; Mo W; Wang C; Li Y; Gu S; Xu Y
Prostate; 2020 May; 80(8):640-652. PubMed ID: 32282098
[TBL] [Abstract][Full Text] [Related]
17. KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy.
Jia J; Zhang HB; Shi Q; Yang C; Ma JB; Jin B; Wang X; He D; Guo P
Theranostics; 2019; 9(19):5464-5477. PubMed ID: 31534497
[TBL] [Abstract][Full Text] [Related]
18. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
19. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer.
Fu B; Wang L; Jia T; Wei Z; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Mao RS; Wang K; Guo J; Chen SS
Prostate; 2023 Nov; 83(15):1415-1429. PubMed ID: 37565264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
